Analysts Think These Stocks Could More Than Double in Value

Despite S&P 500 volatility, three healthcare stocks, Septerna (SEPN), Intellia Therapeutics (NTLA), and Novavax (NVAX), are highlighted for potential growth. Septerna's partnership with Novo Nordisk for obesity and type 2 diabetes treatments could yield over $2 billion, with analysts projecting a near tripling of its stock price. Intellia, focused on genome editing, reported positive trial data and has sufficient cash to fund operations through early 2027, with analysts forecasting a quadrupling of its stock. Novavax received full FDA approval for its COVID-19 vaccine, unlocking a $175 million payment from Sanofi; however, restrictions on the vaccine temper enthusiasm, though analysts still see significant upside.

Analysis

The S&P 500's persistent volatility throughout 2025 underscores a cautious investor sentiment, yet highlights potential opportunities within specific sectors, notably healthcare. Septerna Inc. (NASDAQ: SEPN), a clinical-stage biotechnology firm, has garnered attention following a major partnership with Novo Nordisk A/S (NYSE: NVO) to develop GPCR oral small molecule drugs for obesity and type 2 diabetes. This collaboration provides Septerna with approximately $200 million in near-term payments, bolstering its cash position for R&D, with the deal potentially exceeding $2 billion. Despite shares falling approximately 58% year-to-date, three out of four analysts rate SEPN a Buy, with a consensus price target of $27.00, nearly triple its current $9.48 price. Intellia Therapeutics Inc. (NASDAQ: NTLA), a genome editing company, reported positive two-year follow-up data for its Phase 1 trial of nex-z for ATTRv-PN and maintains a strong cash position of $707 million as of March 31, 2025, sufficient to fund operations through early 2027. While net losses increased year-over-year, net losses per share narrowed. Fourteen out of 21 analysts rate NTLA a Buy, with a consensus price target of $36.90, suggesting a potential quadrupling of its current stock price, though some analysts have lowered price targets while maintaining ratings. Novavax Inc. (NASDAQ: NVAX) presents a higher-risk profile; its recently FDA-approved protein-based COVID-19 vaccine secured a $175 million milestone payment from Sanofi SA (NASDAQ: SNY) and offers a unique non-mRNA option. However, significant FDA restrictions cast doubt on its widespread availability, contributing to share price volatility—a near 25% spike followed by a rapid decline, with the stock down approximately 16% year-to-date. Nevertheless, four of seven analysts recommend NVAX as a Buy, with a consensus target of $19.00, implying over 160% upside from its current $7.29 price.

Key Decisions for Investors

• Investors considering Septerna (SEPN) should weigh the transformative potential of its Novo Nordisk partnership and significant analyst-projected upside against its substantial year-to-date share price decline and inherent clinical-stage biotech risks.
• For Intellia Therapeutics (NTLA), the promising clinical data for nex-z and robust cash runway offer a compelling growth narrative, though the mixed analyst outlook on price targets warrants careful monitoring of ongoing trial progress and R&D execution.
• Novavax (NVAX) represents a high-risk, high-reward situation; while FDA approval and its unique vaccine offer upside, the concurrent FDA restrictions and market reception signal significant uncertainty, requiring a strong risk appetite.
• Given the speculative nature and notable volatility of these biotech stocks, investors should align any exposure with their individual risk tolerance, particularly within the broader uncertain market environment.